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osting by EAbstract Various 2-((2-((5-benzylideneamino)-1,3,4-oxa/thiadiazol-2-yl)methyl)hydrazinyl) methyl)-
benzo[b][1,4]oxa/thiazepin-4(5H)-ones (4a–4l), 2-((2-((5-(4-oxo-2-substitutedphenyl thiazolidin-
3-yl)-1,3,4-oxa/thiadiazol-2-yl)methyl)hydrazinyl)methyl)benzo [b] [1,4]oxa/thiazepin-4(5H)-ones
(5a–5l) and 2-((2-((5-(3-chloro-2-(substitutedphenyl)-4-oxoazetidin-1-yl)-1,3,4-oxa/thia diazol-2-
yl)methyl)hydrazinyl)methyl)benzo[b][1,4]oxa/thiazepin-4(5H)-ones (6a–6l) have been synthesized.
The structures of these compounds have been established by elemental (C, H, N) and spectral
(IR, 1H-NMR and Mass) analysis. The synthesized compounds were screened for their antipsy-
chotic and anticonvulsant activities. Compound 5l was found to be the most active compound of
this series.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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Several organic compounds containing a fused seven membered
heterocyclic ring, i.e., benzoxazepines and benzothiazepines
make up a broad class that attracted attention in the past few
years owing to its wide range of biological activities, especially
antipsychotic (Bajaj et al., 2004; Kaur et al., 2009), anticonvul-
sant (Bajaj et al., 2003a; Nagarajan et al., 1985) and neuroleptic
(Bajaj et al., 2003b). It is interesting to note from chemical liter-
ature that various new pharmacophores like oxadiazole, thiadi-
azole, azetidinone, and thiazolidinone derivatives were also
found to possess wide spectrum of antipsychotic (Kaur et al.,
2010; Sabb et al., 2001 Sadashiva et al., 2009) andanticonvulsant
(Almasirad et al., 2004; Gupta et al., 2008; Agarwal et al., 2006)
activities. In the light of above discussion we report herein the
synthesis of new derivatives of benzoxazepine and benzothiaze-
pine by incorporating above mentioned pharmacophores, with
the hope to possess better antipsychotic and anticonvulsant
activities with lower toxicity.2. Experimental
2.1. Instrumentation
All reagents and solvents used in study are of analytical grade
and procured locally. The progress of the reaction is monitored
by TLC and product are puriﬁed through recrystallization and
purity of the compounds was checked by thin layer chroma-
tography (TLC) performed on silica gel G coated plate of
0.5 mm thickness. The elemental analysis, spectral studies,
IR, and 1H NMR were determined by standard methods. Infrared (IR) spectra were recorded in KBr on Perkin–Elmer-
spectrum RX-I instrument and mmax was recorded in cm
1.
The 1H-NMR spectra were recorded in CDCl3 and DMSO-d6
on Brucker DRX-300 FTNMR instrument.
2.1.1. General procedure for synthesis of Ethyl-2-((4-oxo-4,
5-dihydrobenzo[b] [1,4] oxa/thiazepin-2-yl)methyl)
hydrazinocarboxylate (1a–1b)
To a solution of 2-Hydrazinomethyl-1,5-benzoxa/thiazepin-
4(5H)-ones (2.0 mole) in dry acetone (100 mL), ethylchloro
acetate (2.0 mole) was added dropwise in the presence of anhy-
drous K2CO3 (8 g) in the mixture with stirring. The resulting
mixture was reﬂuxed on a water-bath for about 13 h. The solid
thus obtained was ﬁltered, dried and recrystallized from
appropriate solvents to obtain compounds 1a–1b.
2.1.1.1. Ethyl-2-((4-oxo-4,5-dihydrobenzo[b][1,4]oxazepin-2-
yl)methyl)hydrazine carboxylate (1a)
Yield 82% (Methanol); m.p. 226 C. IR mmax (KBr, cm1):
3340 (NH), 1672 (C‚O), 1611 (C. . .•C of aromatic ring),
1304 (C–N), 1040 (C–O–C). 1H-NMR (300 MHz, dH, CDCl3)
in ppm: 2.30 (t, 3H, CH2CH3), 3.40 (d, 2H, CH2), 3.60 (d, 2H,
CH2CO), 4.28 (q, 2H, CH2CH3), 8.30 (s, 2H, 2· NH exchange-
able with D2O), 6.80–7.61 (m, 5H, 4H, Ar–H+ 1H, CH of
oxazepine ring), 9.71 (ss, 1H, NH of oxazepine ring) ppm;
MS: [M]+ at m/z 291.12. Anal. Calcd. for C14H17N3O4: C,
57.72; H, 5.88; N, 14.42; Found: C, 57.77; H, 4.95; N, 14.40%.
2.1.1.2. Ethyl-2-((4-oxo-4,5-dihydrobenzo[b][1,4]thiazepin-2-
yl)methyl)hydrazine carboxylate (1b)
Yield 75% (Ethanol); m.p. 222 C. IR mmax (KBr, cm1): 3342
(NH), 1670 (C‚O), 1614 (C. . .•C of aromatic ring), 1304 (C–
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3H, CH2CH3), 3.39 (d, 2H, CH2), 3.62 (d, 2H, CH2CO),
4.22 (q, 2H, CH2CH3), 8.31 (s, 2H, 2· NH exchangeable with
D2O), 6.82–7.71 (m, 5H, 4H, Ar–H+ 1H, CH of thiazepine
ring), 9.70 (ss, 1H, NH of thiazepine ring) ppm; MS: [M]+
at m/z 307.37. Anal. Calcd. for C14H17N3O3S: C, 54.71; H,
5.57; N, 13.66; Found: C, 54.70; H, 4.96; N, 13.70%.
2.1.2. General procedure for synthesis of 2-(2-(2-(4-oxo-4,5-
dihydro benzo[b][1,4]oxa/thiazepin-2-yl)methyl)hydrazinyl)
acetyl)hydrazinyl carboxamide (2a–2d)
A mixture of compounds 1a–1b (1.0 mole) and semi/thiosemi-
carbazide (1.0 mole) in 1, 4 dioxan (100 mL) were reﬂuxed on a
water-bath for about 8 h. The excess solvent was removed un-
der reduced pressure and the product recrystallized from suit-
able solvents to give compound 2a/2d.
2.1.2.1. 2-(2-(2-(4-oxo-4,5-dihydrobenzo[b][1,4]oxazepin-2-
yl)methyl)hydrazinyl) acetyl) hydrazinyl carboxamide (2a)
Yield 72% (Ethanol); m.p. 238 C. IR mmax (KBr, cm1): 3341
(NH), 1673 (C‚O), 1615 (C. . .•C of aromatic ring), 1302 (C–
N), 1038 (C–O–C). 1H-NMR (300 MHz, dH, DMSO-d6):
3.28 (d, 2H, CH2), 3.40 (d, 2H, CH2CO), 8.35 (s, 2H, 2· NH
exchangeable with D2O), 8.40 (m, 4H, NHNHCONH2),
6.82–7.80 (m, 5H, 4H, Ar–H+ 1H, CH of oxazepine ring),
9.72 (ss, 1H, NH of oxazepine ring) ppm; MS: [M]+ at m/z
320.30. Anal. Calcd. for C13H16N6O4: C, 48.75; H, 5.03; N,
26.24; Found: C, 48.78; H, 5.02; N, 26.20%.
2.1.2.2. 2-(2-(2-(4-oxo-4,5-dihydrobenzo[b][1,4]oxazepin-2-
yl)methyl)hydrazinyl) acetyl) hydrazinyl carbothioamide (2b)
Yield 77% (Ethanol); m.p. 230 C. IR mmax (KBr, cm1): 3344
(NH), 1130 (C‚S), 1671 (C‚O), 1613 (C. . .•C of aromatic
ring), 1305 (C–N), 1292 (N–N), 1041 (C–O–C). 1H-NMR
(300 MHz, dH, DMSO-d6): 3.24 (d, 2H, CH2CO), 3.38 (d,
2H, CH2), 8.35 (s, 2H, 2· NH exchangeable with D2O), 8.42
(m, 4H, NHNHCSNH2), 6.77–7.79 (m, 5H, 4H, Ar–H + 1H,
CH of oxazepine ring), 9.72 (ss, 1H, NH of oxazepine ring)
ppm; MS: [M]+ at m/z 336.37. Anal. Calcd. for C13H16N6O3S:
C, 46.42; H, 4.79; N, 24.98; Found: C, 46.40; H, 4.80; N,
24.90%.
2.1.2.3. 2-(2-(2-(4-oxo-4,5-dihydrobenzo[b][1,4]thiazepin-2-
yl)methyl)hydrazinyl) acetyl) hydrazinyl carboxamide (2c)
Yield 69% (DMF-Water); m.p. 236 C. IR mmax (KBr,
cm1): 3344 (NH), 1671 (C‚O), 1613 (C. . .•C of aromatic
ring), 1305 (C–N), 1292 (N–N), 695 (C–S–C). 1H-NMR
(300 MHz, dH, CDCl3): 3.26 (d, 2H, CH2), 3.42 (d, 2H,
CH2CO), 8.33 (s, 2H, 2· NH exchangeable with D2O), 8.45
(m, 4H, NHNHCONH2), 6.77–7.79 (m, 5H, 4H, Ar–
H + 1H, CH of thiazepine ring), 9.72 (ss, 1H, NH of thiaze-
pine ring) ppm; MS: [M]+ at m/z 336.37. Anal. Calcd. for
C13H16N6O3S: C, 46.42; H, 4.79; N, 24.98; Found: C, 46.41;
H, 4.81; N, 24.94%.
2.1.2.4. 2-(2-(2-(4-oxo-4,5-dihydrobenzo[b][1,4]thiazepin-2-
yl)methyl)hydrazinyl) acetyl) hydrazinyl carbothioamide (2d)
Yield 68% (Acetone); m.p. 240 C. IR mmax (KBr, cm1): 3346
(NH), 1031 (C‚S), 1680 (C‚O), 1613 (C. . .•C of aromatic
ring), 1305 (C–N), 1292 (N–N), 694 (C–S–C). 1H-NMR
(300 MHz, dH, CDCl3): 3.26 (d, 2H, CH2), 3.39 (d, 2H,CH2CO), 8.37 (s, 2H, 2· NH exchangeable with D2O), 8.44
(m, 4H, NHNHCSNH2), 6.79–7.85 (m, 5H, 4H, Ar–H + 1H,
CH of thiazepine ring), 9.70 (ss, 1H, NH of thiazepine ring)
ppm; MS: [M]+ atm/z 352.44. Anal. Calcd. for C13H16N6O2S2:
C, 44.30; H, 4.58; N, 23.85; Found: C, 44.28; H, 4.55; N,
23.86%.
2.1.3. General procedure for synthesis of 2-((2-((5-Amino-
1,3,4-oxa/thiadiazolyl) methyl)hydrazinyl)methyl]
benzo[b][1,4]oxa/thiazepin-4(5H)-ones (3a–3d)
A solution of compounds 2a–2d (0.6 mole) with conc. H2SO4
(30 mL) was kept overnight at room temperature, then poured
into ice cold water, neutralized with ammonia and extracted
with ether. The ethereal solution was distilled off and the prod-




Yield 70% (Petroleum ether); m.p. 250 C. IR mmax (KBr,
cm1): 3346 (NH), 1672 (C‚O), 1614 (C. . .•C of aromatic
ring), 1580 (C‚N), 1294 (N–N), 1040 (C–O–C). 1H-NMR
(300 MHz, dH, CDCl3): 3.22 (d, 4H, 2· CH2), 4.45 (s, 2H,
C–NH2), 8.37 (s, 2H, 2· NH exchangeable with D2O), 6.97–
7.88 (m, 5H, 4H, Ar–H + 1H, CH of oxazepine ring), 9.70
(ss, 1H, NH of oxazepine ring) ppm; MS: [M]+ at m/z
304.29. Anal. Calcd. for C13H14N6O3: C, 51.65; H, 4.67; N,
27.88; Found: C, 51.55; H, 4.69; N, 27.87%.
2.1.3.2. 2-((2-((5-Amino-1,3,4-thiadiazolyl)methyl)hydrazi-
nyl)methyl]benzo[b][1,4] oxazepin-4(5H)-one (3b)
Yield 69% (Methanol); m.p. 255 C. IR mmax (KBr, cm1):
3344 (NH), 1680 (C‚O), 1616 (C. . .•C of aromatic ring),
1584 (C‚N), 1293 (N–N), 1038 (C–O–C), 692 (C–S–C). 1H-
NMR (300 MHz, dH, CDCl3): 3.25 (d, 4H, 2· CH2), 4.43 (s,
2H, C–NH2), 8.33 (s, 2H, 2· NH exchangeable with D2O),
6.98–7.83 (m, 5H, 4H, Ar–H + 1H, CH of oxazepine ring),
9.72 (ss, 1H, NH of oxazepine ring) ppm; MS: [M]+ at m/z
318.35. Anal. Calcd. for C13H14N6O2S: C, 49.05; H, 4.43; N,
26.40; Found: C, 49.01; H, 4.40; N, 26.39%.
2.1.3.3. 2-((2-((5-Amino-1,3,4-oxadiazolyl)methyl)hydrazi-
nyl)methyl]benzo[b][1,4] thiazepin-4(5H)-one (3c)
Yield 75% (Ethanol); m.p. 257 C. IR mmax (KBr, cm1): 3341
(NH), 1679 (C‚O), 1612 (C. . .•C of aromatic ring), 1582
(C‚N), 1295 (N–N), 1037 (C–O–C), 696 (C–S–C). 1H-NMR
(300 MHz, dH, CDCl3): 3.22 (d, 4H, 2· CH2), 4.45 (s, 2H,
C–NH2), 8.34 (s, 2H, 2· NH exchangeable with D2O), 6.97–
7.88 (m, 5H, 4H, Ar–H + 1H, CH of thiazepine ring), 9.70
(ss, 1H, NH of thiazepine ring) ppm; MS: [M]+ at m/z
318.35. Anal. Calcd. for C13H14N6O2S: C, 49.05; H, 4.43; N,
26.40; Found: C, 49.06; H, 4.43; N, 26.43%.
2.1.3.4. 2-((2-((5-Amino-1,3,4-thiadiazolyl)methyl)hydrazi-
nyl)methyl]benzo[b][1,4] thiazepin-4(5H)-one (3d)
Yield 76% (Methanol); m.p. 251 C. IR mmax (KBr, cm1):
3343 (NH), 1681 (C‚O), 1617 (C. . .•C of aromatic ring),
1580 (C‚N), 1290 (N–N), 692 (C–S–C). 1H-NMR
(300 MHz, dH, DMSOd6): 3.25 (d, 4H, 2· CH2), 4.41 (s, 2H,
C–NH2), 8.39 (s, 2H, 2· NH exchangeable with D2O), 6.89–
7.81 (m, 5H, 4H, Ar–H + 1H, CH of thiazepine ring), 9.71
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274 H. Kaur et al.334.42. Anal Calcd. for C13H14N6OS2: C, 46.69; H, 4.22; N,
25.13; Found: C, 46.70; H, 4.20; N, 25.15%.





methyl)benzo[b][1,4]oxa/thiazepin-4(5H)-one 3a–3d (0.2 mole),
various substituted aromatic aldehydes (0.2 mole) and glacialacetic acid (5 mL) were reﬂuxed in methanol (100 mL) for
about 6 h. The solid mass thus obtained was recrystallized
from appropriate solvents to obtain compounds 4a–4l.
2.1.4.1. 2-(2-(5-(2-hydroxybenzylideneamino)-1,3,4-oxadiazol-
2-yl)methyl)hydrazinyl) methyl) benzo[b] [1,4]oxazepin-
4(5H)-one (4a)
Yield 75% (Acetone); m.p. 275 C. IR mmax (KBr, cm1): 3435
(OH), 3350 (NH), 1690 (C‚O), 1619 (C. . .•C of aromatic ring),
1589 (C‚N), 1570 (N‚CH), 1295 (N–N), 1039 (C–O–C). 1H-
Synthesis and biological evaluation of some new substituted benzoxazepine and benzothiazepine 275NMR (300 MHz, dH, CDCl3): 3.42 (d, 4H, 2· CH2), 5.90 (s,
1H, N‚CH–Ar), 6.64–7.70 (m, 9H, 8H, Ar–H+ 1H, CH of
oxazepine ring), 8.80 (s, 2H, 2· NH exchangeable with
D2O), 9.70 (ss, 1H, NH of oxazepine ring), 11.20 (s, 1H,
OH) ppm; MS: [M]+ at m/z 406.39. Anal. Calcd. for
C20H18N6O4: C, 59.11; H, 4.46; N, 20.68; Found: C, 59.13;
H, 4.43; N, 20.65%.
2.1.4.2. 2-(2-(5-(4-methoxybenzylideneamino)-1,3,4-oxadiazol-
2-yl)methyl)hydra zinyl) methyl)benzo[b] [1,4]oxazepin-
4(5H)-one (4b)
Yield 77% (DMF-Water); m.p. 270 C. IR mmax (KBr, cm1):
3348 (NH), 1688 (C‚O), 1618 (C. . .•C of aromatic ring), 1590
(C‚N), 1572 (N‚CH), 1291 (N–N), 1041 (C–O–C). 1H-
NMR (300 MHz, dH, CDCl3): 3.36 (d, 4H, 2· CH2), 3.52
(s, 3H, OCH3), 5.92 (s, 1H, N‚CH–Ar), 6.61–7.76 (m, 9H,
8H, Ar–H + 1H, CH of oxazepine ring), 8.81 (s, 2H, 2· NH
exchangeable with D2O), 9.71 (ss, 1H, NH of oxazepine ring)
ppm; MS: [M]+ at m/z 420.42. Anal. Calcd. for C21H20N6O4:
C, 59.99;H, 4.79;N, 19.99; Found:C, 60.00;H, 4.80;N, 20.00%.
2.1.4.3. 2-(2-(5-(2-bromobenzylideneamino)-1,3,4-oxadiazol-2-
yl)methyl)hydrazinyl) methyl) benzo[b] [1,4]oxazepin-
4(5H)-one (4c)
Yield 72% (Methanol); m.p. 272 C. IR mmax (KBr, cm1):
3351 (NH), 1690 (C‚O), 1615 (C. . .•C of aromatic ring),
1591 C‚N), 1573 (N‚CH), 1293 (N–N), 1040 (C–O–C),
614 (C–Br). 1H-NMR (300 MHz, dH, CDCl3): 3.38 (d, 4H,
2· CH2), 5.90 (s, 1H, N‚CH–Ar), 6.69–7.78 (m, 9H, 8H,
Ar–H + 1H, CH of oxazepine ring), 8.85 (s, 2H, 2· NH
exchangeable with D2O), 9.70 (ss, 1H, NH of oxazepine ring)
ppm; MS: [M]+ at m/z 469.29. Anal. Calcd. for
C20H17BrN6O4: C, 51.19; H, 3.65; N, 17.91; Found: C,
51.17; H, 3.63; N, 17.90%.
2.1.4.4. 2-(2-(5-(2-hydroxybenzylideneamino)-1,3,4-thiadiazol-
2-yl)methyl)hydra-zinyl) methyl) benzo[b] [1,4]oxazepin-
4(5H)-one (4d)
Yield 78% (Ethanol); m.p. 278 C. IR mmax (KBr, cm1): 3438
(OH), 3350 (NH), 1693 (C‚O), 1617 (C. . .•C of aromatic ring),
1595 (C‚N), 1572 (N‚CH), 1294 (N–N), 1042 (C–O–C), 689
(C–S–C). 1H-NMR (300, dH, CDCl3): 3.36 (d, 4H, 2· CH2),
5.88 (s, 1H, N‚CH–Ar), 6.70–7.79 (m, 9H, 8H, Ar–H + 1H,
CH of oxazepine ring), 8.82 (s, 2H, 2· NH exchangeable with
D2O), 9.72 (ss, 1H, NH of oxazepine ring), 11.18 (s, 1H, OH)
ppm; MS: [M]+ at m/z 422.46. Anal. Calcd. for C20H18N6O3S:
C, 56.80;H, 4.29;N, 19.89; Found:C, 56.87;H, 4.30;N, 19.90%.
2.1.4.5. 2-(2-(5-(4-methoxybenzylideneamino)-1,3,4-thia-
diazol-2-yl)methyl)hydra zinyl) methyl) benzo[b] [1,4]oxaze-
pin-4(5H)-one (4e)
Yield 79% (DMF-Water); m.p. 271 C. IR mmax (KBr, cm1):
3345 (NH), 1693 (C‚O), 1620 (C. . .•C of aromatic ring), 1594
(C‚N), 1574 (N‚CH), 1296 (N–N), 1040 (C–O–C), 698 (C–
S–C). 1H-NMR (300 MHz, dH, CDCl3): 3.39 (d, 4H, 2· CH2),
3.45 (s, 3H, OCH3), 5.91 (s, 1H, N‚CH–Ar), 6.74-7.70 (m,
9H, 8H, Ar–H + 1H, CH of oxazepine ring), 8.85 (s, 2H, 2·
NH exchangeable with D2O), 9.70 (ss, 1H, NH of oxazepine
ring) ppm; MS: [M]+ at m/z 436.49. Anal. Calcd. for
C21H20N6O3S: C, 57.79; H, 4.62; N, 19.25; Found: C, 57.80;
H, 4.61; N, 19.24%.2.1.4.6. 2-((2-((5-(2-bromobenzylideneamino)-1,3,4-thidiazol-
2-yl)methyl)hydrazinyl) methyl) benzo[b] [1,4]oxazepin-
4(5H)-one (4f)
Yield 74% (Methanol); m.p. 274 C. IR mmax (KBr, cm1):
3345 (NH), 1695 (C‚O), 1623 (C. . .•C of aromatic ring),
1592 (C‚N), 1576 (N‚CH), 1293 (N–N), 1041 (C–O–C),
698 (C–S–C), 611 (C–Br). 1H-NMR (300 MHz, dH, CDCl3):
3.43 (d, 4H, 2· CH2), 5.87 (s, 1H, N‚CH–Ar), 6.79–7.88
(m, 9H, 8H, Ar–H + 1H, CH of oxazepine ring), 8.86 (s,
2H, 2· NH exchangeable with D2O), 9.72 (ss, 1H, NH of oxa-
zepine ring) ppm; MS: [M]+ at m/z 485.36. Anal. Calcd. for
C20H17BrN6O2S: C, 49.49; H, 3.53; N, 17.32; Found: C,
49.50; H, 3.57; N,17.30%.
2.1.4.7. 2-((2-((5-(2-hydroxybenzylideneamino)-1,3,4-oxa-
diazol-2-yl)methyl)hydra zinyl) methyl) benzo[b][1,4]thiaze-
pin-4(5H)-one (4g)
Yield 76% (Acetone); m.p. 272 C. IR mmax (KBr, cm1): 3450
(OH), 3351 (NH), 1689 (C‚O), 1620 (C. . .•C of aromatic ring),
1594 (C‚N), 1578 (N‚CH), 1290 (N–N), 1040 (C–O–C), 698
(C–S–C). 1H-NMR (300 MHz, dH, CDCl3): 3.42 (d, 4H, 2·
CH2), 5.82 (s, 1H, N‚CH–Ar), 6.75–7.74 (m, 9H, 8H, Ar–
H+ 1H, CH of thiazepine ring), 8.80 (s, 2H, 2· NH exchange-
able with D2O), 9.70 (ss, 1H, NH of thiazepine ring), 11.22 (s,
1H, OH) ppm; MS: [M]+ at m/z 422.46. Anal. Calcd. for
C20H18N6O3S: C, 56.86; H, 4.29; N, 18.89; Found: C, 56.84;
H, 4.30; N, 18.88%.
2.1.4.8. 2-((2-((5-(4-methoxybenzylideneamino)-1,3,4-oxa-
diazol-2-yl)methyl)hydrazi- nyl) methyl)benzo [b][1,4]thiaze-
pin-4(5H)-one (4h)
Yield 72% (Petroleum ether); m.p. 270 C. IR mmax (KBr, cm1):
3351 (NH), 1692 (C‚O), 1621 (C. . .•C of aromatic ring), 1588
(C‚N), 1579 (N‚CH), 1292 (N–N), 1043 (C–O–C), 697 (C–
S–C). 1H-NMR (300 MHz, dH, CDCl3): 3.38 (d, 4H, 2· CH2),
3.43 (s, 3H, OCH3), 5.91 (s, 1H, N‚CH–Ar), 6.75–7.72 (m,
9H, 8H, Ar–H + 1H, CH of thiazepine ring), 8.83 (s, 2H, 2·
NH exchangeable with D2O), 9.72 (ss, 1H, NH of thiazepine
ring) ppm; MS: [M]+ at m/z 436.49. Anal. Calcd. for
C21H20N6O3S: C, 57.79; H, 4.62; N, 19.25; Found: C, 57.80;
H, 4.64; N, 19.26%.
2.1.4.9. 2-((2-((5-(2-bromobenzylideneamino)-1,3,4-oxa-
diazol-2-yl)methyl)hydrazinyl)methyl) benzo [b] [1,4]thiaze-
pin-4(5H)-one (4i)
Yield 78% (Ethanol); m.p. 278 C. IR mmax (KBr, cm1): 3354
(NH), 1687 (C‚O), 1624 (C. . .•C of aromatic ring), 1594
(C‚N), 1580 (N‚CH), 1294 (N–N), 1042 (C–O–C), 685 (C–
S–C), 611 (C–Br). 1H-NMR (300 MHz, dH, CDCl3): 3.46 (d,
4H, 2· CH2), 5.80 (s, 1H, N‚CH–Ar), 6.74–7.73 (m, 9H, 8H,
Ar–H+ 1H, CH of thiazepine ring), 8.82 (s, 2H, 2· NH
exchangeable with D2O), 9.70 (ss, 1H, NH of thiazepine ring)
ppm; MS: [M]+ at m/z 485.36. Anal. Calcd. for C20H17N6O2S:
C, 49.40;H, 3.53;N, 17.32; Found:C, 49.38;H, 3.55;N, 17.33%.
2.1.4.10. 2-((2-((5-(2-hydroxybenzylideneamino)-1,3,4-thia-
diazol-2-yl)methyl)hydrazi nyl) methyl)benzo [b][1,4]thiaze-
pin-4(5H)-one (4j)
Yield 75% (Methanol); m.p. 277 C. IR mmax (KBr, cm1): 3452
(OH), 3344 (NH), 1686 (C‚O), 1620 (C. . .•C of aromatic ring),
1590 (C‚N), 1575 (N‚CH), 1293 (N–N), 682 (C–S–C). 1H-
NMR (300 MHz, dH, CDCl3): 3.40 (d, 4H, 2· CH2), 5.87
276 H. Kaur et al.(s, 1H, N‚CH–Ar), 6.70–7.69 (m, 9H, 8H, Ar–H + 1H,CH of
thiazepine ring), 8.81 (s, 2H, 2· NH exchangeable with D2O),
9.72 (ss, 1H, NH of thiazepine ring), 11.20 (s, 1H, OH) ppm;
MS: [M]+ at m/z 438.53. Anal. Calcd. for C20H18N6O2S2: C,




Yield 76% (DMF-Water); m.p. 269 C. IR mmax (KBr, cm1):
3342 (NH), 1685 (C‚O), 1624 (C. . .•C of aromatic ring), 1593
(C‚N), 1572 (N‚CH), 1291 (N–N), 697 (C–S–C). 1H-NMR
(300 MHz, dH, DMSOd6): 3.42 (d, 4H, 2· CH2), 3.48 (s, 3H,
OCH3), 5.90 (s, 1H, N‚CH–Ar), 6.64–7.70 (m, 9H, 8H, Ar–
H+ 1H, CH of thiazepine ring), 8.80 (s, 2H, 2· NH exchange-
able with D2O), 9.70 (ss, 1H, NH of thiazepine ring) ppm; MS:
[M]+ at m/z 452.55. Anal. Calcd. for C21H20N6O2S2: C, 55.73;




Yield 73% (Petroleum ether); m.p. 270 C. IR mmax (KBr, cm1):
3340 (NH), 1684 (C‚O), 1624 (C. . .•C of aromatic ring), 1591
(C‚N), 1571 (N‚CH), 1292 (N–N), 684 (C–S–C), 614 (C–
Br). 1H-NMR (300 MHz, dH, CDCl3): 3.43 (d, 4H, 2· CH2),
5.87 (s, 1H, N‚CH–Ar), 6.64–7.76 (m, 9H, 8H, Ar–
H+ 1H, CH of thiazepine ring), 8.86 (s, 2H, 2· NH exchange-
able with D2O), 9.73 (ss, 1H, NH of thiazepine ring) ppm; MS:
[M]+ at m/z 501.42. Anal. Calcd. for C20H17BrN6OS2: C,
47.91; H, 3.42; N, 16.76; Found: C, 47.87; H, 3.40; N, 16.80%




To a solution of compounds 4a–4l (0.05 mole) and thioglycolic
acid (0.05 mole) inmethanol (100 mL)ZnCl2 (a pinch)was added
and the reaction mixture was kept for four days at room temper-
ature and the mixture was reﬂuxed for 10 h on water bath, dis-
tilled off, poured into ice-cold water, ﬁltered and ﬁnally




Yield 70% (Methanol); m.p. 297 C. IR mmax (KBr, cm1):
3448 (OH), 3342 (NH), 1710 (C‚O), 1680 (C‚O), 1623
(C. . .•C of aromatic ring), 1606 (C‚N), 1290 (N–N), 1035
(C–O–C). 1H-NMR (300 MHz, dH, DMSO-d6): 3.40 (d, 4H,
2· CH2), 3.85 (s, 2H, CH2 of thiazolidinone ring), 5.90 (s,
1H, CH–Ar), 6.90–8.01 (m, 9H, 8H, Ar–H + 1H, CH of oxa-
zepine ring), 8.40 (s, 2H, 2· NH exchangeable with D2O), 9.71
(ss, 1H, NH of oxazepine ring), 11.19 (s, 1H, OH) ppm; MS:
[M]+ at m/z 480.40. Anal. Calcd. for C22H20N6O5S: C,




Yield 73% (Ethanol); m.p. 298 C. IR mmax (KBr, cm1): 3340
(NH), 1724 (C‚O), 1689 (C‚O), 1625 (C. . .•C of aromaticring), 1604 (C‚N), 1293 (N–N), 1226 (OCH3), 1037 (C–O–
C). 1H-NMR (300 MHz, dH, DMSOd6): 3.41 (d, 4H, 2·
CH2), 3.50 (s, 3H, OCH3), 3.86 (s, 2H, CH2 of thiazolidinone
ring), 5.93 (s, 1H, CH–Ar), 6.98–8.00 (m, 9H, 8H, Ar–
H+ 1H, CH of oxazepine ring), 8.43 (s, 2H, 2· NH exchange-
able with D2O), 9.70 (ss, 1H, NH of oxazepine ring) ppm; MS:
[M]+ at m/z 494.52. Anal. Calcd. for C23H22N6O5S: C, 55.86;
H, 4.48; N, 16.99; Found: C, 55.87; H, 4.50; N, 17.00%.
2.1.5.3. 2-((2-((5-(4-oxo-2(2-bromophenyl)thiazolidin-3-yl)-1,
3,4-oxadiazol-2-yl) methyl) hydrazinyl) methyl) benzo[b]
[1,4]oxazepin-4(5H)-one (5c)
Yield 76% (Methanol); m.p. 295 C. IR mmax (KBr, cm1):
3342 (NH), 1700 (C‚O), 1683 (C‚O), 1624 (C. . .•C of aro-
matic ring), 1603 (C‚N), 1292 (N–N), 1040 (C–O–C), 615
(C–Br). 1H-NMR (300 MHz, dH, CDCl3): 3.42 (d, 4H, 2·
CH2), 3.87 (s, 2H, CH2 of thiazolidinone ring), 5.92 (s, 1H,
CH–Ar), 6.99–7.96 (m, 9H, 8H, Ar–H + 1H, CH of oxazepine
ring), 8.43 (s, 2H, 2· NH exchangeable with D2O), 9.71 (ss,
1H, NH of oxazepine ring) ppm; MS: [M]+ at m/z 543.39.
Anal. Calcd. for C22H19BrN6O4S: C, 48.63; H, 3.52; N,




Yield 78% (Acetone); m.p. 299 C. IR mmax (KBr, cm1): 3448
(OH), 3342 (NH), 1705 (C‚O), 1686 (C‚O), 1623 (C. . .•C of
aromatic ring), 1606 (C‚N), 1290 (N–N), 1041 (C–O–C), 688
(C–S–C). 1H-NMR (300 MHz, dH, CDCl3): 3.44 (d, 4H, 2·
CH2), 3.85 (s, 2H, CH2 of thiazolidinone ring), 5.90 (s, 1H,
CH–Ar), 6.90–8.01 (m, 9H, 8H, Ar–H + 1H, CH of oxazepine
ring), 8.41 (s, 2H, 2· NH exchangeable with D2O), 9.72 (ss,
1H, NH of oxazepine ring), 11.17 (s, 1H, OH) ppm; MS:
[M]+ at m/z 496.56. Anal. Calcd. for C22H20N6O4S2: C,




Yield 74% (Methanol); m.p. 287 C. IR mmax (KBr, cm1):
3345 (NH), 1714 (C‚O), 1684 (C‚O), 1627 (C. . .•C of aro-
matic ring), 1602 (C‚N), 1294 (N–N), 1227 (OCH3), 1042
(C–O–C), 691 (C–S–C). 1H-NMR (300 MHz, dH, CDCl3):
3.40 (d, 4H, 2· CH2), 3.46 (s, 3H, OCH3), 3.82 (s, 2H, CH2
of thiazolidinone ring), 5.92 (s, 1H, CH–Ar), 6.90–8.01 (m,
9H, 8H, Ar–H+ 1H, CH of oxazepine ring), 8.45 (s, 2H, 2·
NH exchangeable with D2O), 9.71 (ss, 1H, NH of oxazepine
ring) ppm; MS: [M]+ at m/z 510.59. MS: [M]+ at m/z. Anal.
Calcd. for C23H22N6O4S2: C, 54.10; H, 4.34; N, 16.46; Found:
C, 54.13; H, 4.34; N, 16.48%.
2.1.5.6. 2-((2-((5-(4-oxo-2(2-bromophenyl)thiazolidin-3-yl)-
1,3,4-thiadiazol-2-yl) methyl) hydrazinyl) methyl) benzo[b]
[1,4]oxazepin-4(5H)-one (5f)
Yield 75% (DMF–Water); m.p. 294 C. IR mmax (KBr, cm1):
3341 (NH), 1721 (C‚O), 1676 (C‚O), 1624 (C. . .•C of aro-
matic ring), 1610 (C‚N), 1291 (N–N), 1040 (C–O–C), 694
(C–S–C), 612 (C–Br). 1H-NMR (300 MHz, dH, DMSO-d6):
3.45 (d, 4H, 2· CH2), 3.80 (s, 2H, CH2 of thiazolidinone ring),
5.87 (s, 1H, CH–Ar), 6.87–7.85 (m, 9H, 8H, Ar–H + 1H, CH
of oxazepine ring), 8.40 (s, 2H, 2· NH exchangeable with
Synthesis and biological evaluation of some new substituted benzoxazepine and benzothiazepine 277D2O), 9.73 (ss, 1H, NH of oxazepine ring) ppm; MS: [M]
+ at
m/z 559.46. Anal. Calcd. for C22H19BrN6O3S2: C, 47.23; H,
3.42; N, 14.28; Found: C, 47.30; H, 3.46; N, 14.25%.
2.1.5.7. 2-((2-((5-(4-oxo-2-(2-hydroxyphenyl)thiazolidin-3-
yl)-1,3,4-oxadiazol-2-yl) methyl) hydrazinyl methyl) benzo[b]
[1,4]thiazepin-4(5H)-one (5g)
Yield 74% (Ethanol); m.p. 290 C. IR mmax (KBr, cm1): 3438
(OH), 3345 (NH), 1700 (C‚O), 1679 (C‚O), 1627 (C. . .•C of
aromatic ring), 1602 (C‚N), 1294 (N–N), 1042 (C–O–C), 691
(C–S–C). 1H-NMR (300 MHz, dH, CDCl3): 3.46 (d, 4H, 2·
CH2), 3.86 (s, 2H, CH2 of thiazolidinone ring), 5.82 (s, 1H,
CH–Ar), 6.88–7.78 (m, 9H, 8H, Ar–H+ 1H, CH of thiazepine
ring), 8.43 (s, 2H, 2·NH exchangeable with D2O), 9.70 (ss, 1H,
NH of thiazepine ring), 11.17 (s, 1H,OH) ppm;MS: [M]+ atm/z
496.56. Anal. Calcd. for C22H20BrN6O4S2: C, 53.21; H, 4.06; N,
16.92; Found: C, 53.26; H, 4.03; N, 16.99%.
2.1.5.8. 2-((2-((5-(4-oxo-2(4-methoxyphenyl)thiazolidin-3-
yl)-1,3,4-oxadiazol-2-yl) methyl) 2.1.5. hydrazinyl) methyl)
benzo[b][1,4]thiazepin-4(5H)-one (5h)
Yield 74% (Petroleum ether); m.p. 297 C. IR mmax (KBr, cm1):
3341 (NH), 1712 (C‚O), 1688 (C‚O), 1624 (C. . .•C of aro-
matic ring), 1610 (C‚N), 1291 (N–N), 1038 (C–O–C), 694
(C–S–C). 1H-NMR (300 MHz, dH, DMSO-d6): 3.39 (d, 4H,
2· CH2), 3.44 (s, 3H, OCH3), 3.87 (s, 2H, CH2 of thiazolidi-
none ring), 5.84 (s, 1H, CH–Ar), 6.84–7.85 (m, 9H, 8H, Ar–
H + 1H, CH of thiazepine ring), 8.42 (s, 2H, 2· NH exchange-
able with D2O), 9.71 (ss, 1H, NH of thiazepine ring) ppm; MS:
[M]+ at m/z 510.59. Anal. Calcd. for C23H22N6O4S2: C, 54.10;
H, 4.34; N, 16.46; Found: C, 54.11; H, 4.36; N, 16.45%.
2.1.5.9. 2-((2-((5-(4-oxo-2(2-bromophenyl)thiazolidin-3-yl)-
1,3,4-oxadiazol-2-yl) methyl) hydrazinyl) methyl)benzo[b]
[1,4]thiazepin-4(5H)-one (5i)
Yield 76% (Acetone); m.p. 295 C. IR mmax (KBr, cm1): 3438
(OH), 3345 (NH), 1720 (C‚O), 1680 (C‚O), 1627 (C. . .•C of
aromatic ring), 1602 (C‚N), 1294 (N–N), 1041 (C–O–C), 691
(C–S–C), 614 (C–Br). 1H-NMR (300 MHz, dH, DMSO-d6):
3.34 (d, 4H, 2· CH2), 3.89 (s, 2H, CH2 of thiazolidinone ring),
5.83 (s, 1H, CH–Ar), 6.88–7.87 (m, 9H, 8H, Ar–H + 1H, CH
of thiazepine ring), 8.43 (s, 2H, 2· NH exchangeable with
D2O), 9.71 (ss, 1H, NH of thiazepine ring) ppm; MS: [M]
+
at m/z 559.46. Anal. Calcd. for C22H19BrN6O3S2: C, 47.23;
H, 3.42; N, 15.02; Found: C, 47.20; H, 3.40; N, 15.06%.
2.1.5.10. 2-((2-((5-(4-oxo-2-(2-hydroxyphenyl)thiazolidin-3-
yl)-1,3,4-thiadiazol-2-yl)methyl) hydra zinyl methyl)benzo[b]
[1,4]thiazepin-4(5H)-one (5j)
Yield 79% (Methanol); m.p. 297 C. IR mmax (KBr, cm1):
3432 (OH), 3345 (NH), 1700 (C‚O), 1686 (C‚O), 1627
(C. . .•C of aromatic ring), 16110 (C‚N), 1294 (N–N), 690
(C–S–C). 1H-NMR (300 MHz, dH, CDCl3): 3.44 (d, 4H, 2·
CH2), 3.85 (s, 2H, CH2 of thiazolidinone ring), 5.92 (s, 1H,
CH–Ar), 6.90–7.79 (m, 9H, 8H, Ar–H+ 1H, CH of thiazepine
ring), 8.41 (s, 2H, 2· NH exchangeable with D2O), 9.73 (ss,
1H, NH of thiazepine ring), 11.16 (s, 1H, OH) ppm; MS:
[M]+ at m/z 512.63. Anal. Calcd. for C22H20N6O3S3: C,
51.55; H, 3.93; N, 16.39; Found: C, 51.57; H, 3.92; N, 16.40%.
2.1.5.11. 2-((2-((5-(4-oxo-2(4-methoxyphenyl)thiazolidin-3-
yl)-1,3,4-thiadiazol-2-yl)methyl) hydrazinyl) methyl)benzo[b][1,4]thiazepin-4(5H)-one (5k). Yield 73% (Acetone); m.p.
292 C. IR mmax (KBr, cm1): 3346 (NH), 1716 (C‚O), 1679
(C‚O), 1630 (C. . .•C of aromatic ring), 1610 (C‚N), 1293
(N–N), 692 (C–S–C). 1H-NMR (300 MHz, dH, CDCl3): 3.37
(d, 4H, 2· CH2), 3.41 (s, 3H, OCH3), 3.86 (s, 2H, CH2 of thia-
zolidinone ring), 5.89 (s, 1H, CH–Ar), 6.93–8.00 (m, 9H, 8H,
Ar–H + 1H, CH of thiazepine ring), 8.44 (s, 2H, 2· NH
exchangeable with D2O), 9.72 (ss, 1H, NH of thiazepine ring
ppm;. MS: [M]+ at m/z 526.65. Anal. Calcd. for
C23H22N6O3S3: C, 54.45; H, 4.21; N, 15.96; Found: C, 54.45;




Yield 72% (Ethanol); m.p. 298 C. IR mmax (KBr, cm1): 3438
(OH), 3345 (NH), 1725 (C‚O), 1672 (C‚O), 1629 (C. . .•C of
aromatic ring), 1605 (C‚N), 1294 (N–N), 691 (C–S–C), 613
(C–Br) cm1; 1H-NMR (300 MHz, dH, CDCl3) d in ppm:
3.40 (d, 4H, 2· CH2), 3.85 (s, 2H, CH2 of thiazolidinone ring),
5.90 (s, 1H, CH–Ar), 6.90–8.01 (m, 9H, 8H, Ar–H + 1H, CH
of thiazepine ring), 8.40 (s, 2H, 2· NH exchangeable with
D2O), 9.71 (ss, 1H, NH of thiazepine ring) ppm; MS: [M]
+
at m/z 575.52. Anal. Calcd. for C22H19BrN6O2S3: C, 45.91;
H, 3.33; N, 14.60; Found: C, 45.90; H, 3.38; N, 14.62%.




To a stirred solution of compounds 4a–4l (0.05 mole) and tri-
ethyl amine in dioxan (100 mL), chloro acetyl chloride
(0.05 mole) was added dropwise at 0–5 C temperature. The
reaction mixture was stirred for about 6 h and the precipitated
amine hydrochloride was ﬁltered off. The ﬁltrate was reﬂuxed
for 2 h and the separated solid was recrystallized from appro-




Yield 77% (Methanol); m.p. 289 C. IR mmax (KBr, cm1): 3448
(OH), 3350 (NH), 1710 (C‚O), 1685 (C‚O), 1624 (C. . .•C of
aromatic ring), 1604 (C‚N), 1292 (N–N), 1038 (C–O–C). 1H-
NMR (300 MHz, dH, CDCl3): 3.38 (d, 4H, 2· CH2), 3.80 (d,
1H, CH–Cl of azetidinone ring), 5.82 (d, 1H, CH–Ar), 6.80-
7.82 (m, 9H, 8H, Ar–H+ 1H, CH of oxazepine ring), 8.35 (s,
2H, 2·NH exchangeable with D2O), 9.70 (ss, 1H,NH of oxaze-
pine ring), 11.13 (s, 1H, OH) ppm; MS: [M]+ at m/z 482.88.
Anal. Calcd. for C22H19ClN6O5: C, 54.72; H, 3.93; N, 17.40;




Yield 75% (Acetone); m.p. 291 C. IR mmax (KBr, cm1): 3352
(NH), 1708 (C‚O), 1682 (C‚O), 1628 (C. . .•C of aromatic
ring), 1610 (C‚N), 1294 (N–N), 1225 (OCH3), 1036 (C–O–
C). 1H-NMR (300 MHz, dH, CDCl3): 3.36 (d, 4H, 2· CH2),
3.41 (s, 3H, OCH3), 3.82 (d, 1H, CH–Cl of azetidinone ring),
5.85 (d, 1H, CH–Ar), 6.73–7.86 (m, 9H, 8H, Ar–H + 1H,
278 H. Kaur et al.CH of oxazepine ring), 8.32 (s, 2H, 2· NH exchangeable with
D2O), 9.72 (ss, 1H, NH of oxazepine ring) ppm; MS: [M]
+ at
m/z 496.40. Anal. Calcd. for C23H21ClN6O5: C, 55.59; H, 4.26;




Yield 74% (DMF-Water); m.p. 288 C. IR mmax (KBr, cm1):
3349 (NH), 1711 (C‚O), 1675 (C‚O), 1625 (C. . .•C of aro-
matic ring), 1605 (C‚N), 1295 (N–N), 1035 (C–O–C), 615
(C–Br). 1H-NMR (300 MHz, dH, CDCl3): 3.37 (d, 4H, 2·
CH2), 3.83 (d, 1H, CH–Cl of azetidinone ring), 5.80 (d, 1H,
CH–Ar), 6.82–7.80 (m, 9H, 8H, Ar–H+ 1H, CH of oxazepine
ring), 8.38 (s, 2H, 2· NH exchangeable with D2O), 9.71 (ss,
1H, NH of oxazepine ring) ppm; MS: [M]+ at m/z 545.77.
Anal. Calcd. for C22H18ClBrN6O4: C, 48.41; H, 3.32; N,




Yield 73% (Ethanol); m.p. 295 C. IR mmax (KBr, cm1): 3446
(OH), 3350 (NH), 1712 (C‚O), 1687 (C‚O), 1629 (C. . .•C of
aromatic ring), 1608 (C‚N), 1293 (N–N), 1040 (C–O–C), 684
(C–S–C). 1H-NMR (300 MHz, dH, CDCl3): 3.32 (d, 4H, 2·
CH2), 3.82 (d, 1H, CH–Cl of azetidinone ring), 5.82 (d, 1H,
CH–Ar), 6.82-7.82 (m, 9H, 8H, Ar–H+ 1H, CH of oxazepine
ring), 8.38 (s, 2H, 2· NH exchangeable with D2O), 9.73 (ss,
1H, NH of oxazepine ring), 11.20 (s, 1H, OH) ppm; MS:
[M]+ at m/z 498.94. Anal. Calcd. for C22H19ClN6O4S: C,




Yield 73% (Acetone); m.p. 299 C. IR mmax (KBr, cm1):
3347 (NH), 1714 (C‚O), 1685 (C‚O), 1627 (C. . .•C of aro-
matic ring), 1605 (C‚N), 1220 (OCH3), 1292 (N–N), 1041
(C–O–C) 690 (C–S–C). 1H-NMR (300 MHz, dH, CDCl3):
3.36 (d, 4H, 2· CH2), 3.43 (s, 3H, OCH3), 3.84 (d, 1H,
CH–Cl of azetidinone ring), 5.85 (d, 1H, CH–Ar), 6.79-7.80
(m, 9H, 8H, Ar–H+ 1H, CH of oxazepine ring), 8.35 (s,
2H, 2· NH exchangeable with D2O), 9.70 (ss, 1H, NH of
oxazepine ring) ppm; MS: [M]+ at m/z 512.10. Anal. Calcd.
for C23H21ClN6O4S: C, 53.85; H, 4.13; N, 16.38; Found: C,
53.85; H, 4.15; N, 16.34%.
2.1.6.6. 2-((2-((5-(3-chloro-2-oxo-4-(2-bromophenyl)azetidin-
1-yl)-1,3,4-thiadiazol-2-yl) methyl) hydrazinyl) methyl)
benzo[b][1,4]oxazepin-4(5H)-one (6f).
Yield 72% (Petroleum ether); m.p. 298 C. IR mmax (KBr,
cm1): 3348 (NH), 1710 (C‚O), 1688 (C‚O), 1628
(C. . .•C of aromatic ring), 1607 (C‚N), 1292 (N–N), 1041
(C–O–C), 676 (C–S–C), 612 (C–Br). 1H-NMR (300 MHz,
dH, CDCl3): 3.40 (d, 4H, 2· CH2), 3.80 (d, 1H, CH–Cl of
azetidinone ring), 5.82 (d, 1H, CH–Ar), 6.87–7.77 (m, 9H,
8H, Ar–H+ 1H, CH of oxazepine ring), 8.85 (s, 2H, 2·
NH exchangeable with D2O), 9.72 (ss, 1H, NH of oxazepine
ring) ppm; MS: [M]+ at m/z 561.84. Anal. Calcd. for
C22H18ClBrN6O3S: C, 47.03; H, 3.23; N, 14.96; Found: C,
47.09; H, 3.22; N, 14.97%.2.1.6.7. 2-((2-((5-(3-chloro-2-oxo-4-(2-hydroxyphenyl)azeti-
din-1-yl)-1,3,4-oxadiazol-2-yl) methyl) hydrazinyl)methyl)
benzo[b][1,4]thiazepine-4(5H)-one (6g)
Yield 78% (Ethanol); m.p. 294 C. IR mmax (KBr, cm1): 3445
(OH), 3349 (NH), 1726 (C‚O), 1690 (C‚O), 1630 (C. . .•C of
aromatic ring), 1606 (C‚N), 1295 (N–N), 1038 (C–O–C) 686
(C–S–C). 1H-NMR (300 MHz, dH, CDCl3): 3.38 (d, 4H, 2·
CH2), 3.78 (d, 1H, CH–Cl of azetidinone ring), 5.79 (d, 1H,
CH–Ar), 6.92–7.83 (m, 9H, 8H, Ar–H + 1H, CH of thiazepine
ring), 8.31 (s, 2H, 2· NH exchangeable with D2O), 9.70 (ss,
1H, NH of thiazepine ring), 11.17 (s, 1H, OH) ppm; MS:
[M] + at m/z. Anal. Calcd. for C22H19ClN6O4S: C, 52.96; H,




Yield 73% (DMF-Water); m.p. 295 C. IR mmax (KBr, cm1):
3350 (NH), 1719 (C‚O), 1686 (C‚O), 1629 (C. . .•C of aro-
matic ring), 1605 (C‚N), 1292 (N–N), 1226 (OCH3), 1040
(C–O–C) 691 (C–S–C). 1H-NMR (300 MHz, dH, CDCl3):
3.37 (d, 4H, 2· CH2), 3.41 (s, 3H, OCH3), 3.80 (d, 1H, CH–
Cl of azetidinone ring), 5.84 (d, 1H, CH–Ar), 6.83–7.90 (m,
9H, 8H, Ar–H + 1H, CH of thiazepine ring), 8.37 (s, 2H, 2·
NH exchangeable with D2O), 9.71 (ss, 1H, NH of thiazepine
ring) ppm; MS: [M]+ at m/z 512.97. Anal. Calcd. for
C23H21ClN6O4S: C, 53.85; H, 4.13; N, 16.38; Found: C,




Yield 72% (Petroleum ether); m.p. 289 C. IR mmax (KBr, cm1):
3348 (NH), 1710 (C‚O), 1680 (C‚O), 1628 (C. . .•C of aro-
matic ring), 1610 (C‚N), 1292 (N–N), 1039 (C–O–C), 672
(C–S–C), 612 (C–Br). 1H-NMR (300 MHz, dH, CDCl3): 3.38
(d, 4H, 2· CH2), 3.80 (d, 1H, CHCl of azetidinone ring),
5.82 (d, 1H, CH–Ar), 6.80–7.82 (m, 9H, 8HAr–H+ 1H, CH
of thiazepine ring), 8.35 (s, 2H, 2· NH exchangeable with
D2O), 9.72 (ss, 1H, NH of thiazepine ring)ppm; MS: [M]
+ at
m/z 561.84. Anal. Calcd. for C22H18ClBrN6O3S: C, 47.03; H,




Yield 75% (Acetone); m.p. 287 C. IR mmax (KBr, cm1): 3448
(OH), 3350 (NH), 1710 (C‚O), 1676 (C‚O), 1626 (C. . .•C of
aromatic ring), 1604 (C‚N), 1294 (N–N), 685 (C–S–C). 1H-
NMR (300 MHz, dH, CDCl3): 3.34 (d, 4H, 2· CH2), 3.79 (d,
1H, CH–Cl of azetidinone ring), 5.83 (d, 1H, CH–Ar), 6.82–
7.84 (m, 9H, 8H, Ar–H + 1H, CH of thiazepine ring), 8.31
(s, 2H, 2· NH exchangeable with D2O), 9.73 (ss, 1H, NH of
thiazepine ring), 11.20 (s, 1H, OH) ppm; MS: [M]+ at m/z
515.01. Anal. Calcd. for C22H19ClN6O3S2: C, 51.31; H, 3.72;




Yield 72% (Ethanol); m.p. 290 C. IR mmax (KBr, cm1): 3352
(NH), 1708 (C‚O), 1678 (C‚O), 1625 (C. . .•C of aromatic
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1H-NMR (300 MHz, dH, CDCl3): 3.35 (d, 4H, 2· CH2),
3.44 (s, 3H, OCH3), 3.89 (d, 1H, CH–Cl of azetidinone ring),
5.91 (d, 1H, CH–Ar), 6.78–7.80 (m, 9H, 8H, Ar–H + 1H,
CH of thiazepine ring), 8.40 (s, 2H, 2· NH exchangeable with
D2O), 9.72 (ss, 1H, NH of thiazepine ring) ppm; MS: [M]
+ at
m/z 529.03. Anal. Calcd. for C23H21ClN6O3S2: C, 52.22; H,




Yield 73% (Methanol); m.p. 298 C. IR mmax (KBr, cm1):
3349 (NH), 1711 (C‚O), 1671 (C‚O), 1628 (C. . .•C of aro-
matic ring), 1611 (C‚N), 1295 (N–N), 689 (C–S–C), 611
(C–Br). 1H-NMR (300 MHz, dH, CDCl3): 3.33 (d, 4H, 2·
CH2), 3.87 (d, 1H, CH–Cl of azetidinone ring), 5.93 (d, 1H,
CH–Ar), 6.81–7.84 (m, 9H, 8H, Ar–H + 1H, CH of thiazepine
ring), 8.41 (s, 2H, 2· NH exchangeable with D2O), 9.70 (ss,
1H, NH of thiazepine ring) ppm; MS: [M]+ at m/z 577.90.
Anal. Calcd. for C22H18ClBrN6O2S2; C, 45.72; H, 3.14; N,
14.54; Found: C, 45.70; H, 3.15; N, 14.58%.3. Results and discussion
All the compounds were evaluated for antipsychotic activity by
recording their responses towards amphetamine induced ste-
reotyped behaviour, cataleptic behaviour and rotarod perfor-
mance test and for anticonvulsant activity by the MES test,
at a dose of 30 mg/kg each. Pharmacological data of the com-
pounds have been given in Tables 1–3.
3.1. Antipsychotic activity
3.1.1. Amphetamine induced stereotyped behaviour
The compounds 4a–4l showed mild to moderate response
against amphetamine induced stereotyped behaviour. Further-
more, compounds 5c–5h, 5k, 6c, 6f, 6i, 6k and 6l showed
interesting results. Furthermore, compounds 5i and 5l (2-
bromophenyl moiety) have shown the most potent response
because these compounds completely antagonized the stereo-
typed behaviour induced by amphetamine.
3.1.2. Cataleptic behaviour
Compounds 4l, 5c–5e, 5g–5j, 6f, 6h and 6l signiﬁcantly antag-
onized the cataleptic behaviour. However, compound 5l
showed the most potent response because this compound did
not exhibit any cataleptic behaviour.
3.2. Rotarod performance test
Compounds 4a–4l exhibited moderate results in rotarod per-
formance test, but compound 4l showed better response in
comparison to the compounds 4a–4k. In the next step, com-
pounds 5a–5l (having substituted thiazolidinone ring) exhib-
ited potent results (i.e. 94.0–102.6 s). Among the compounds
5a–5l, compound 5l showed the most potent result (i.e.
94.0 s) in rotarod performance test. On the other side, com-
pounds 6a–6l exhibited different results (i.e. 100.0–104.6 s),
but compound 6l showed good activity in rotarod test.3.3. Anticonvulsant activity
Among the compounds 4a–4l, compounds 4j, 4k and 4l showed
good response (i.e. 50-60%) against MES test. The compounds
5a–5l exhibited varying degrees (50-90%) of anticonvulsant
activity; moreover, compound 5l (having 2-bromophenyl ring
at 2nd position of thiazolidinone ring) has shown 90% anticon-
vulsant activity which was more potent than the standard drug
phenytoin sodium (30 mg/kg). On the other side, compounds
6a–6l, substituted with different azetidinone moieties at the
2nd position of benzoxazepine and benzothiazepine ring have
shown30–70%protection.Moreover, the effect of 2-bromophe-
nyl moiety was found to be similar in the case of 5l and 6l.
4. Conclusion
While considering the synthesized compounds of this series we
may conclude that:
 Benzothiazepine derivatives showed more potent response
than benzoxazepine derivatives.
 Compounds with thiadiazole moiety showed better antipsy-
chotic and anticonvulsant activity in comparison to the
compounds substituted with oxadiazole moiety.
 Compounds having 2-bromophenyl moiety at second posi-
tion of benzothiazepine ring (i.e. compounds 5l and 6l)
showed better biological activities than the other substi-
tuted compounds.5. Biological methods
All the newly synthesized compounds 4a–4l, 5a–5l and 6a–6l
were tested for their antipsychotic and anticonvulsant activi-
ties. The effect of unknown compounds was compared with
the standard drugs and the propylene glycol treated group
served as a control.
5.1. Antipsychotic activity
Effect on amphetamine induced stereotyped behaviour (SB):
It was done by the method of Castall and Naylor (1974).
Before the administration of drugs, the animals were fasted
for 12 h and were deprived of food during experiment.
Amphetamine (4 mg/kg, i.p.) was used to induce the stereo-
typed behaviour (SB) in albino rats. The intensity of SB was
assessed for 60 min after the test compounds treatment, using
the following scoring system. Periodic snifﬁng = 1 score, con-
tinuous snifﬁng = 2 score, periodic biting, gnawing or lick-
ing = 3 score and continuous biting, gnawing or licking = 4
score. The maximum intensity of SB scored by each rat in
the group was taken to compute the mean value of the group.
Chlorpromazine (4 mg/kg, i.p.) was used as standard and was
injected 30 min. before the challenge, while propylene glycol
(0.5 mL i.p.) or test compounds were given 20 min prior to
the injection of amphetamine.
5.1.1. Induction of catalepsy
It was performed according to the method of Castall and Nay-
lor (1974). According this method, the front limbs of the rat
were placed over the wooden block of 8 cm high and the time
Table 1 Antipsychotic and anticonvulsant activity of compounds (5a–5l).
Comp.
No.














P.G.* – 0.5 ml 3.8 – 120.0 0
P.S. – – – 30 – – – 80***
CPZ – – – 4.0 ml 0.0 – 100.0 0
HPL* – – – 0.5 ml – 1.8 – 0
4a 2-OH O O 30 2.6 2.4 116.8 20 >1000
4b 4-OCH3 O O 30 2.4 2.2 116.0 20 >1000
4c 2-Br O O 30 2.6 2.0 110.2 30 >1000
4d 2-OH O S 30 2.4 2.2 110.0 20 >1000
4e 4-OCH3 O S 30 2.2 2.0 114.4 20 >1000
4f 2-Br O S 30 2.2 2.0 108.8 40 >1000
4g 2-OH S O 30 2.2 1.8 110.6 30 >1000
4h 4-OCH3 S O 30 2.0 1.8 112.2 30 >1000
4i 2-Br S O 30 1.0 2.0 108.8 40 >1000
4j 2-OH S S 30 2.2 1.6 108.8 50* >1000
4k 4-OCH3 S S 30 1.8 1.8 108.4 50
* >1000
4l 2-Br S S 30 1.0 0.6 104.2 60** >1000
















Table 2 Antipsychotic and anticonvulsant activity of compounds (5a–5l).
Comp.
No.














P.G.* – 0.5 ml 3.8 – 120.0 0
P.S. – – – 30 – – – 80***
CPZ – – – 4.0 ml 0.0 – 100.0 0
HPL* – – – 0.5 ml – 1.8 – 0
5a 2-OH O O 30 0.8 1.0 102.6 50* >1000
5b 4-OCH3 O O 30 1.0 1.2 102.2 50
* >1000
5c 2-Br O O 30 0.6 0.4 100.4 60** >1000
5d 2-OH O S 30 0.4 0.6 102.2 50* >1000
5e 4-OCH3 O S 30 0.6 0.4 102.6 60
** >1000
5f 2-Br O S 30 0.4 0.8 100.4 60** >1000
5g 2-OH S O 30 0.6 0.2 102.2 50* >1000
5h 4-OCH3 S O 30 0.2 0.2 100.4 50
* >1000
5i 2-Br S O 30 0.0 0.4 100.2 70*** >1000
5j 2-OH S S 30 0.8 0.2 100.2 60** >1000
5k 4-OCH3 S S 30 0.2 0.8 100.8 70
*** >1000
5l 2-Br S S 30 0.0 0.0 94.0 90*** >1000

























































Table 3 Antipsychotic and anticonvulsant activity of compounds (6a–6l).
Comp.
No.














P.G.* – 0.5 ml 3.8 – 120.0 0
P.S. – – – 30 – – – 80***
CPZ – – – 4.0 ml 0.0 – 100.0 0
HPL* – – – 0.5 ml – 1.8 – 0
6a 2-OH O O 30 1.2 2.0 104.6 30 >1000
6b 4-OCH3 O O 30 1.0 1.6 103.0 40 >1000
6c 2-Br O O 30 0.6 1.0 102.4 50* >1000
6d 2-OH O S 30 1.0 1.4 102.6 40 >1000
6e 4-OCH3 O S 30 0.8 1.6 104.6 50
* >1000
6f 2-Br O S 30 0.6 0.4 104.4 50* >1000
6g 2-OH S O 30 1.0 1.2 102.8 40 >1000
6h 4-OCH3 S O 30 1.0 0.2 100.4 50
* >1000
6i 2-Br S O 30 0.4 0.8 102.6 60** >1000
6j 2-OH S S 30 1.0 1.0 102.2 60** >1000
6k 4-OCH3 S S 30 0.6 0.8 102.8 60
*** >1000
6j 2-Br S S 30 0.2 0.2 100.0 70** >1000
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mals maintaining the imposed posture for more than 10 s were
considered to be cataleptic. Animals were tested for catalepsy
by using the scoring system to maintain the imposed posture
0–10 s = 0 score, 11–30 s = 1 score, 31–60 s = 2 score, 61–
120 s = 3 score, after injecting propylene glycol (0.5 mL, i.p.)
or test compounds or haloperidol (0.5 mg/kg, i.p.) as standard.
5.1.2. Rotarod performance test
The rotarod performance was essentially the same as de-
scribed by Dunham and Miya (1957). It is a measure of
strength and coordinated movement of animals. The animals
were given a training session on the rotarod (rotating at
6 rpm) a day before the test session. As soon as the rat fell
off the rotarod, it was immediately placed back. Training
was terminated when the rat remained on the rod continu-
ously for 2 min. On the second day, after the administration
of test compound, the rats were given the trials on the rota-
rod for 60 min and the cumulated time spent on the rotarod
was recorded with a cut off of 2 min.
5.2. Anticonvulsant activity
5.2.1. Supramaximal electroshock seizure (SMES) pattern test
This activity was performed by following the method of To-
man et al., 1946; Qufeng et al., 2009. Male mice were divided
into the groups of 10 animals each. The mice were treated with
the test compounds and phenytoin sodium at a dose of 30 mg/
kg p.o. After 1h they were subjected to the shock of 25 mA by
convulsiometer through ear electrodes for 0.25 s Abolition of
the hind limb tonic extensor component of the seizure is de-
ﬁned as protection, and the results are expressed as number
of animals protected/number of animals tested.
Approximate lethal dose (LD50): The compounds were
investigated for their acute toxicity (LD50) which was esti-
mated by following the method of smith 1960.Acknowledgements
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